The journal retracts the article, An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis [1], cited above, with the mutual agreement and support of the authors.
Following publication, concerns were brought to the attention of the publisher regarding the use of unpublished trial data without appropriate permission and potential concerns about the accuracy of the data.
Adhering to our complaints procedure, an investigation was conducted that confirmed a lack of appropriate permission from the authors and the conference organizers (Worldsymposium) in using incomplete trial data of anakira in MPS III NCT04018755, incorrectly presenting a placebo in the trial, using a table of incorrect data in the supplementary information, as well as the preliminary nature of this data meaning they could not be yet fully be relied upon to support the main findings of this study, leading to errors in values and calculations. This article is therefore retracted.
This retraction was approved by the Editor-in-Chief of the journal Pharmaceutics.
The authors agree to this retraction.
Reference
- Wiesinger, A.-M.; Bigger, B.; Giugliani, R.; Lampe, C.; Scarpa, M.; Moser, T.; Kampmann, C.; Zimmermann, G.; Lagler, F.B. RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).